JHBP CY Holdings logo

6998 - JHBP CY Holdings News Story

HK$19 0.1  0.6%

Last Trade - 03/03/21

Market Cap £862.0m
Enterprise Value £845.3m
Revenue £1.30m
Position in Universe 939th / 6141

BUZZ- Chinese biopharmaceutical group JHBP shines in Hong Kong debut

Wed 7th October, 2020 2:54am
** Shares of Chinese biopharmaceutical group JHBP (CY)
Holdings Ltd  6998.HK  trade as high as HK$30.80 each in Hong
Kong trading debut, up 28.3% from the IPO price of HK$24 apiece
    ** Stock is the most actively traded share by turnover in
early trade 
    ** Stock later trims gain to HK$30.45, still up 26.9% from
the IPO price
    ** Shanghai-based JHBP, which develops and commercializes
oncology and autoimmune drugs, offered 119.88 mln shares at
HK$24 apiece in Hong Kong IPO, raising HK$2.88 bln ($371.6 mln)
to fund R&D, clinical trials, and for expansion of drug pipeline
 urn:newsml:reuters.com:*:nFWN2GJ0LE
    ** Twelve cornerstone investors, comprising Hillhouse
Capital, Orbimed, Tigermed, Temasek Holdings, Pacific Asset
Management, Matrix, Logos, Ping An Insurance, Tudor, 3W, Athos
and YF Life, subscribed for a total $187 mln worth of shares
    ** The Hang Seng China enterprises index  .HSCE  eases 0.2%,
while the benchmark index  .HSI  slides 0.1%
($1 = 7.7500 Hong Kong dollars)

 (Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.